Industry:
Drug Manufacturing,
Pharmaceuticals,
Biotechnology
Tranzyme Pharma is developing proprietary therapeutic candidates from its own medicinal chemistry platform to treat underserved diseases of the GI tract such as post-operative ileus (POI), gastroparesis, irritable bowel syndrome-diarrhea type, and functional dyspepsia. The Company's novel small molecules target two validated, druggable G protein-coupled receptors found within the GI tract-ghrelin and motilin. By targeting these two receptors, Tranzyme Pharma has identified "mechanism-based" agents that act directly at the site of pathophysiological disturbance. The Company recently announced positive preclinical data for its lead ghrelin agonists for treating POI and diabetic
Contact with Tranzyme , Inc.:
3001 12E Avenue Nord
Sherbrooke,
Quebec
J1H 5N4
Canada
Tel: (819) 820-6840
Fax: (819) 820-6841
Web Site: www.tranzyme.com
Instant Messenger:
N/A